Desarrollo de nuevas formulaciones orales de naproxeno para el tratamiento de la migraña
Loading...
Download
Official URL
Full text at PDC
Publication date
2021
Defense date
10/11/2020
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
La migraña es una de las afecciones que más población padece en todo el mundo, por ese motivo, es de gran interés mejorar y/o desarrollar nuevos tratamientos que traten y ayuden a las personas que la sufren. Actualmente los tratamientos se pueden dividir en 2 modalidades: los tratamientos agudos y los tratamientos profilácticos. Existen multitud de medicamentos para tratar estas modalidades, pero los que aparecen indicados en ambas, son los AINES. Dentro de los AINES, el naproxeno es el que mejores características reúne para intentar perfeccionar su formulación. Las razones principales para centrarse en el naproxeno son dos. La primera es su gran uso generalizado; y la segunda es su posible margen de mejora, esto es debido tanto a su alta dosis de inicio (1000mg), como a su lenta liberación (Tmax 2-4h). Por ello, lo que se pretende es tanto mejorar su biodisponibilidad, como el tiempo de efecto, disminuyendo así la dosis efectiva y el tiempo de actuación...
Migraine is one of the most worldwide-spread health conditions. Hence, it is of pronounced interest to improve current treatments and/or develop novel treatments that would improve patients’ health.Currently, treatments can be divided into 2 modalities based on the status of the condition: acute treatments, for ongoing migraine episodes, and prophylactic treatments, as preventive treatment. Out of the large group of medicines being used as treatment, NSAIDs products are commonly used at both modalities. Within NSAIDs products, naproxen’s characteristics has shown great feasibility when used for optimizing formulation.Naproxen has been selected due to two main reasons. Firstly, its widespread use; and secondly, its potential margin of improvement, as a result of both its high starting dose (1000mg), and its slow release (Tmax 2-4h). Thus, the aspiration would be to improve both its bioavailability and the time of effect, consequently decreasing the effective dose and the time of action...
Migraine is one of the most worldwide-spread health conditions. Hence, it is of pronounced interest to improve current treatments and/or develop novel treatments that would improve patients’ health.Currently, treatments can be divided into 2 modalities based on the status of the condition: acute treatments, for ongoing migraine episodes, and prophylactic treatments, as preventive treatment. Out of the large group of medicines being used as treatment, NSAIDs products are commonly used at both modalities. Within NSAIDs products, naproxen’s characteristics has shown great feasibility when used for optimizing formulation.Naproxen has been selected due to two main reasons. Firstly, its widespread use; and secondly, its potential margin of improvement, as a result of both its high starting dose (1000mg), and its slow release (Tmax 2-4h). Thus, the aspiration would be to improve both its bioavailability and the time of effect, consequently decreasing the effective dose and the time of action...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, Departamento de Farmacia Galénica y Tecnología Alimentaria, leída el 10-11-2020